Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insights into the role of Fc gamma receptors (FcgammaRs) genetic variations in monoclonal antibody-based anti-cancer therapy.

Recent patents on anti-cancer drug discovery - 1 Nov 2010

Concetti Fabio, Napolioni Valerio

Abstract excerpt

Recently, the field of oncology has witnessed the introduction of several effective chemotherapeutic agents. Still, not all cancers respond to the use of conventional chemotherapy and thus combination therapy is an emerging weapon in the battle against cancer. There is emerging evidence in support of the use of Monoclonal antibodies (MoAbs) in cancer therapy. The mechanisms behind their efficacy are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibody-Dependent Cell Cytotoxicity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Genetic Variation

Share to Immunotherapy

Share to Neoplasms

Share to Receptors, IgG

Source

Identifiers

PMID: 20594185
DOI: 10.2174/157489210791760490

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insights into the role of Fc gamma receptors (FcgammaRs) genetic variations in monoclonal antibody-based anti-cancer therapy.PMID 20594185Read ↗

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancerSemantic proximity Read ↗

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myelomaSemantic proximity Read ↗

Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.Semantic proximity Read ↗

Engineered antibody Fc variants with enhanced effector function.Semantic proximity Read ↗

Effect of FCGR2A and FCGR3A variants on CLL outcome.Semantic proximity Read ↗

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.Semantic proximity Read ↗

Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment.Semantic proximity Read ↗

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.Semantic proximity Read ↗

Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors.Semantic proximity Read ↗

Isotype selection for antibody-based cancer therapySemantic proximity Read ↗

FCGR3A polymorphism : It is helpful for the management of diffuse large B-cell lymphomaSemantic proximity Read ↗

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.